NCT00095433View on ClinicalTrials.gov

Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
Macular Degeneration
Interventions
DRUG

rhuFab V2 (ranibizumab)

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY